Ardelyx, Inc. (ARDX): Long-Term Debt
$202.83M
As of 2025-12-31
$251.82M
As of 2026-06-30
+96.6%
3-year compound annual growth
+31.9%
5-year compound annual growth
| Period ended | Long-Term Debt | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $202.83M | +34.5% | 2026-02-19, Balance as of period end |
| 2024-12-31 | $150.85M | +202.8% | 2026-02-19, Balance as of period end |
| 2023-12-31 | $49.82M | +86.5% | 2025-02-20, Balance as of period end |
| 2022-12-31 | $26.71M | -17.2% | 2023-03-02, Balance as of period end |
| 2021-12-31 | $32.26M | -36.5% | 2022-02-28, Balance as of period end |
| 2020-12-31 | $50.79M | +1.5% | 2021-03-08, Balance as of period end |
| 2019-12-31 | $50.01M | -3.8% | 2020-03-06, Balance as of period end |
| 2018-12-31 | $51.98M | n/a | 2019-03-06, Balance as of period end |
Long-Term Debt at similar companies
| Company | Year ended | Long-Term Debt | Change YoY |
|---|---|---|---|
| Ardelyx, Inc. (ARDX) | 2025-12-31 | $202.83M | +34.5% |
| Sinovac Biotech Ltd (SVA) | 2025-12-31 | $494.86M | +31.7% |
| Arcutis Biotherapeutics, Inc. (ARQT) | 2025-12-31 | $108.96M | +1.6% |
| MannKind Corp (MNKD) | 2025-12-31 | $354.64M | +883.7% |
| BridgeBio Pharma, Inc. (BBIO) | 2025-12-31 | $2.01B | n/a |
| HUTCHMED (China) Ltd (HCM) | 2025-12-31 | $93.16M | +12.5% |
| Evolus, Inc. (EOLS) | 2025-12-31 | $146.10M | +20.2% |
| Xeris Biopharma Holdings, Inc. (XERS) | 2025-12-31 | $220.34M | -5.1% |
| Insmed Inc (INSM) | 2025-12-31 | $546.77M | -51.3% |
Compare ARDX, SVA, ARQT, MNKD side by side · Screen every company in Pharmaceutical Preparations ↗